MapLight, supported by Novo, reaches a valuation of $787 million following a rise in shares during its Nasdaq debut.
(Reuters) – Maplight Therapeutics went public on the Nasdaq on Monday, achieving a valuation of $787 million. This marked the first IPO under a seldom-used regulatory guideline following the U.S. government shutdown. The Redwood City, California-based company, which focuses on treatments for central nervous system disorders, saw its shares open at $19 each—almost 12% higher […]